Glenmark Pharmaceuticals announced that the Baddi manufacturing unit of the company was inspected by the leading European regulator, SUKL (State Institute for Drug control), Czech Republic in the week of 21 October 2019.
The European regulator has just issued a certificate of compliance for the facility stating that it complies with the principles and guidelines of Good Manufacturing Practice laid down in the directive 2003/94/EC which stipulates the requirements to fulfil GMP recommendations of WHO.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
